Best On Osteoarthritis From the ACR Annual Meeting

Surgery. Shots. Supplements. What's new for patients with osteoarthritis? Read RheumNet Editorial Board member Roy Altman MD's favorite presentations on the subject from ACR2014.


psoriatic arthritis

Agents that target the TH17-interleukin pathway show promise in psoriatic arthritis, as alternatives for patients who don't benefit from TNFα blockers. This slide show describes their mode of action and potential.

The JAK1 and JAK2 inhibitor baricitinib has shown significant results in a second Phase 3 trial for rheumatoid arthritis.

The first study to ask about variance between physicians and patients in judging the severity of psoriatic arthritis shows that, as with rheumatoid arthritis, they don't reach similar conclusions.

Antinuclear antibody testing and DEXA both appear on a new Canadian list of rheumatology tests to avoid and on a similar 2013 list from the American College of Rheumatology. There are interesting differences in the other 3 choices.

juvenile arthritis

The TNF-α blocker improved growth rates for many preadolescent girls with juvenile arthritis, especially those who hadn't been taking steroids.

FDA boxed warnings about hepatitis B virus (HBV) reactivation risk relate only to ofatumumab and rituximab. Eminent hepatologists say everyone destined for immunosuppression should be tested for HBV first.

Clinical remission is not necessarily good reason to stop treatment for rheumatoid arthritis. New MRI data show that many patients continue to show inflammation and osteitis, even if they no longer have symptoms.


Subscribe to Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.